ImmunityBio, Inc. (IBRX) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $7.18, but acceptable to hold if already in. Reasons: Negative momentum; Elevated risk factors.
ImmunityBio is a biotech commercializing ANKTIVA (nogapendekin alfa inbakicept) for BCG-unresponsive NMIBC, approved in the U.S., UK, Saudi Arabia, and EU. ANKTIVA generated ~$113M net revenue in 2025 (700% YoY growth) and is being evaluated across NSCLC, lymphoma, and other... Read more
Hold if already holding. Not a fresh buy at $7.18, but acceptable to hold if already in. Reasons: Negative momentum; Elevated risk factors. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Score 5.9/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 50d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent developments
updated 2026-06-15Recent Developments — ImmunityBio, Inc.
Latest news
- NEWS IBRX stock in spotlight: ImmunityBio to unveil fresh Anktiva and BCG data next week - MSN — MSN positive
- NEWS IBRX stock slips overnight: Founder teases Turkey push, says AI cancer cell robot is ‘almost there’ - MSN — MSN neutral
- NEWS IBRX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15 - GuruFocus — GuruFocus neutral
- NEWS ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout - Seeking Alpha — Seeking Alpha positive
- NEWS ImmunityBio: One Approval Away From A Multi-Billion Dollar Breakout (NASDAQ:IBRX) - Seeking Alpha — Seeking Alpha positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $7.18, but acceptable to hold if already in. Reasons: Negative momentum; Elevated risk factors. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Target $11.05 (+53.9%), stop $6.65 (−8.0%), A.R:R 5.0:1. Score 5.9/10, moderate confidence.
Take-profit target: $11.05 (+54.5% upside). Target $11.05 (+53.9%), stop $6.65 (−8.0%), A.R:R 5.0:1. Stop-loss: $6.65.
Negative momentum; Elevated risk factors; Value-trap signals (2/5): Margin compression (op margin -157.9%), Negative free cash flow.
ImmunityBio, Inc. trades at a P/E of N/A (forward 118.3). TrendMatrix value score: 5.5/10. Verdict: Hold.
10 analysts cover IBRX with a consensus score of 4.3/5. Average price target: $13.
What does ImmunityBio, Inc. do?ImmunityBio is a biotech commercializing ANKTIVA (nogapendekin alfa inbakicept) for BCG-unresponsive NMIBC, approved in...
ImmunityBio is a biotech commercializing ANKTIVA (nogapendekin alfa inbakicept) for BCG-unresponsive NMIBC, approved in the U.S., UK, Saudi Arabia, and EU. ANKTIVA generated ~$113M net revenue in 2025 (700% YoY growth) and is being evaluated across NSCLC, lymphoma, and other solid tumors.